Headlands Technologies LLC Boosts Stake in Edwards Lifesciences Co. (NYSE:EW)

Headlands Technologies LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 115.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,362 shares of the medical research company’s stock after buying an additional 2,873 shares during the period. Headlands Technologies LLC’s holdings in Edwards Lifesciences were worth $409,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of EW. Martin Capital Advisors LLP lifted its holdings in shares of Edwards Lifesciences by 0.5% during the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after purchasing an additional 128 shares during the last quarter. Legacy Wealth Asset Management LLC raised its stake in Edwards Lifesciences by 0.8% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after acquiring an additional 134 shares during the last quarter. DMC Group LLC raised its stake in Edwards Lifesciences by 4.5% in the 4th quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock worth $272,000 after acquiring an additional 154 shares during the last quarter. Granite Harbor Advisors Inc. raised its stake in Edwards Lifesciences by 4.2% in the 3rd quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock worth $265,000 after acquiring an additional 155 shares during the last quarter. Finally, Stableford Capital II LLC raised its stake in Edwards Lifesciences by 2.7% in the 4th quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock worth $449,000 after acquiring an additional 155 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on EW. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Stifel Nicolaus increased their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Wells Fargo & Company increased their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Citigroup increased their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $93.33.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $1.58 during midday trading on Friday, reaching $86.43. The company had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The company has a market capitalization of $52.02 billion, a P/E ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm’s fifty day simple moving average is $90.28 and its 200-day simple moving average is $78.85. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total transaction of $944,130.00. Following the sale, the vice president now directly owns 39,503 shares in the company, valued at approximately $3,390,542.49. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.